Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 A circulating anticoagulant in gamma-1A-multiple myeloma: its modification by penicillin.

Literature DB >> 5843717

A circulating anticoagulant in gamma-1A-multiple myeloma: its modification by penicillin.

H I Glueck, R Hong.

Abstract

Entities: Chemical Disease

Mesh：

Substances：

Year: 1965 PMID： 5843717 PMCID： PMC289687 DOI： 10.1172/JCI105294

Source DB: PubMed Journal: J Clin Invest ISSN： 0021-9738 Impact factor: 14.808

× No keyword cloud information.

34 in total

1. Pathogenesis of the coagulation defect developing during pathological plasma proteolytic ("fibrinolytic") states. II. The significance, mechanism and consequences of defective fibrin polymerization.

Authors: N ALKJAERSIG; A P FLETCHER; S SHERRY
Journal: J Clin Invest Date: 1962-04 Impact factor: 14.808

2. Inherited factor-VII defect in a Negro family.

Authors: H I GLUECK; J M SUTHERLAND
Journal: Pediatrics Date: 1961-02 Impact factor: 7.124

3. A simple chromatographic method for preparation of gamma globulin.

Authors: H B LEVY; H A SOBER
Journal: Proc Soc Exp Biol Med Date: 1960-01

4. Application of continuous flow electrophoresis to the study of the blood coagulation proteins. II. The hemophilias (A and B).

Authors: J H LEWIS; W R MERCHANT
Journal: J Clin Invest Date: 1959-11 Impact factor: 14.808

5. Diagnosis and control of the hemophilioid states with the partial thromboplastin time (PTT) test.

Authors: N F RODMAN; E M BARROW; J B GRAHAM
Journal: Am J Clin Pathol Date: 1958-06 Impact factor: 2.493

6. Macroglobulinaemia; effect of macroglobulins on prothrombin conversion accelerators.

Authors: L A LONG; J L RIOPELLE; M FRANCOEUR; A PARE; P POIRIER; M GEORGESCO; G COLPRON
Journal: Can Med Assoc J Date: 1955-11-01 Impact factor: 8.262

7. The utilization of a synthetic substrate (TAMe) to measure the plasma prothrombin in coagulation disorders.

Authors: H I GLUECK
Journal: J Lab Clin Med Date: 1957-01

8. Thrombocytopenia and abnormal bleeding in multiple myeloma.

Authors: T N JAMES; R W MONTO; J W REBUCK
Journal: Ann Intern Med Date: 1953-12 Impact factor: 25.391

9. ELECTROPHORETIC ISOLATION OF A CIRCULATING ANTICOAGULANT.

Authors: F L Munro; M P Munro
Journal: J Clin Invest Date: 1946-11 Impact factor: 14.808

10. Refractoriness in hemophilia to coagulation-promoting agents: whole blood and plasma derivatives.

Authors: W B FROMMEYER; R D EPSTEIN; F H L TAYLOR
Journal: Blood Date: 1950-05 Impact factor: 22.113

10 in total

Review 1. The immunoglobulins: a review.

Authors: N H Martin
Journal: J Clin Pathol Date: 1969-03 Impact factor: 3.411

2. Acquired hemophilia in a patient with myeloma.

Authors: L S Loftus; W N Arnold
Journal: West J Med Date: 1994-02

3. Acquired inhibitor to human factor VIII associated with paraproteinaemia and subsequent development of chronic lymphatic leukaemia.

Authors: P R Kelsey; M J Leyland
Journal: Br Med J (Clin Res Ed) Date: 1982-07-17

4. The immunologic character of acquired inhibitors of antihemophilic globulin (factor 8) and the kinetics of their interaction with factor 8.

Authors: S S Shapiro
Journal: J Clin Invest Date: 1967-02 Impact factor: 14.808

Review 5. Rituximab and intravenous immunoglobulin (IVIG) for the management of acquired factor VIII inhibitor in multiple myeloma: case report and review of literature.

Authors: Jameel Muzaffar; Lakshmikanth Katragadda; Sajjad Haider; Ali Javed; Elias Anaissie; Saad Usmani
Journal: Int J Hematol Date: 2011-12-15 Impact factor: 2.490